

Please type a plus sign (+) inside this box [ + ]

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

### UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 5543P004

(maximum 12 characters)

First Named Inventor J.J. Garcia-Luna-Aceves

Title: SYSTEM AND METHOD FOR RESOLVING NETWORK LAYER ANYCAST ADDRESSES TO NETWORK LAYER UNICAST ADDRESSES

Express Mail Label No. EL617184959US

ADDRESS TO: **Assistant Commissioner for Patents**  
**Box Patent Application**  
**Washington, D. C. 20231**

#### APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ **Fee Transmittal Form (e.g., PTO/SB/17)**  
(Submit an original, and a duplicate for fee processing)
2. ☐ **Applicant Claims Small Entity Status. (37 CFR 1.27)**
3. ☒ **Specification (Total Pages 42)**  
(preferred arrangement set forth below)
  - Descriptive Title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference sequence listing, a table,  
or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ **Drawings(s) (35 USC 113) (Total Sheets 5)**
5. ☒ **Oath or Declaration (Total Pages 5)**
  - a. ☐ Newly Executed (Original or Copy)
  - b. ☐ Copy from a Prior Application (37 CFR 1.63(d))  
(for Continuation/Divisional with Box 17 completed)
    - i. ☐ DELETIONS OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
  - c. ☒ Unsigned.
6. ☐ **Application Data Sheet. (37 CFR 1.76)**
7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. ☐ Specification Sequence Listing on
    - i. ☐ CD-ROM or CD-R (2 copies), or
    - ii. ☐ paper
  - c. ☐ Statement verifying identity of above copies

Variable	Mean	SD	Min	Max
Age	35.5	10.5	18	65
Gender	1.0	0.0	0	1
Marital status	1.0	0.0	0	1
Education	12.5	1.5	9	16
Income	1.5	0.5	1	2
Occupation	1.0	0.0	0	1
Health status	1.0	0.0	0	1
Life satisfaction	1.0	0.0	0	1
Life expectancy	1.0	0.0	0	1
Life expectancy squared	1.0	0.0	0	1
Life expectancy cubed	1.0	0.0	0	1
Life expectancy to the fourth power	1.0	0.0	0	1
Life expectancy to the fifth power	1.0	0.0	0	1
Life expectancy to the sixth power	1.0	0.0	0	1
Life expectancy to the seventh power	1.0	0.0	0	1
Life expectancy to the eighth power	1.0	0.0	0	1
Life expectancy to the ninth power	1.0	0.0	0	1
Life expectancy to the tenth power	1.0	0.0	0	1
Life expectancy to the eleventh power	1.0	0.0	0	1
Life expectancy to the twelfth power	1.0	0.0	0	1
Life expectancy to the thirteenth power	1.0	0.0	0	1
Life expectancy to the fourteenth power	1.0	0.0	0	1
Life expectancy to the fifteenth power	1.0	0.0	0	1
Life expectancy to the sixteenth power	1.0	0.0	0	1
Life expectancy to the seventeenth power	1.0	0.0	0	1
Life expectancy to the eighteenth power	1.0	0.0	0	1
Life expectancy to the nineteenth power	1.0	0.0	0	1
Life expectancy to the twentieth power	1.0	0.0	0	1
Life expectancy to the twenty-first power	1.0	0.0	0	1
Life expectancy to the twenty-second power	1.0	0.0	0	1
Life expectancy to the twenty-third power	1.0	0.0	0	1
Life expectancy to the twenty-fourth power	1.0	0.0	0	1
Life expectancy to the twenty-fifth power	1.0	0.0	0	1
Life expectancy to the twenty-sixth power	1.0	0.0	0	1
Life expectancy to the twenty-seventh power	1.0	0.0	0	1
Life expectancy to the twenty-eighth power	1.0	0.0	0	1
Life expectancy to the twenty-ninth power	1.0	0.0	0	1
Life expectancy to the thirtieth power	1.0	0.0	0	1
Life expectancy to the thirty-first power	1.0	0.0	0	1
Life expectancy to the thirty-second power	1.0	0.0	0	1
Life expectancy to the thirty-third power	1.0	0.0	0	1
Life expectancy to the thirty-fourth power	1.0	0.0	0	1
Life expectancy to the thirty-fifth power	1.0	0.0	0	1
Life expectancy to the thirty-sixth power	1.0	0.0	0	1
Life expectancy to the thirty-seventh power	1.0	0.0	0	1
Life expectancy to the thirty-eighth power	1.0	0.0	0	1
Life expectancy to the thirty-ninth power	1.0	0.0	0	1
Life expectancy to the fortieth power	1.0	0.0	0	1
Life expectancy to the forty-first power	1.0	0.0	0	1
Life expectancy to the forty-second power	1.0	0.0	0	1
Life expectancy to the forty-third power	1.0	0.0	0	1
Life expectancy to the forty-fourth power	1.0	0.0	0	1
Life expectancy to the forty-fifth power	1.0	0.0	0	1
Life expectancy to the forty-sixth power	1.0	0.0	0	1
Life expectancy to the forty-seventh power	1.0	0.0	0	1
Life expectancy to the forty-eighth power	1.0	0.0	0	1
Life expectancy to the forty-ninth power	1.0	0.0	0	1
Life expectancy to the fiftieth power	1.0	0.0	0	1
Life expectancy to the fifty-first power	1.0	0.0	0	1
Life expectancy to the fifty-second power	1.0	0.0	0	1
Life expectancy to the fifty-third power	1.0	0.0	0	1
Life expectancy to the fifty-fourth power	1.0	0.0	0	1
Life expectancy to the fifty-fifth power	1.0	0.0	0	1
Life expectancy to the fifty-sixth power	1.0	0.0	0	1
Life expectancy to the fifty-seventh power	1.0	0.0	0	1
Life expectancy to the fifty-eighth power	1.0	0.0	0	1
Life expectancy to the fifty-ninth power	1.0	0.0	0	1
Life expectancy to the sixtieth power	1.0	0.0	0	1
Life expectancy to the sixty-first power	1.0	0.0	0	1
Life expectancy to the sixty-second power	1.0	0.0	0	1
Life expectancy to the sixty-third power	1.0	0.0	0	1
Life expectancy to the sixty-fourth power	1.0	0.0	0	1
Life expectancy to the sixty-fifth power	1.0	0.0	0	1
Life expectancy to the sixty-sixth power	1.0	0.0	0	1
Life expectancy to the sixty-seventh power	1.0	0.0	0	1
Life expectancy to the sixty-eighth power	1.0	0.0	0	1
Life expectancy to the sixty-ninth power	1.0	0.0	0	1
Life expectancy to the seventieth power	1.0	0.0	0	1

- 18A. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:**

**Applicant(s):** Also include a Preliminary Amendment to amend the specification to claim priority. For CONTINUATION AND DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18B. Statement under 37 CFR 3.73(b) for continuing application:  
The undersigned states that \_\_\_\_\_ (name of assignee) is the assignee of the entire right, title, and interest in the accompanying patent application by virtue of an assignment recorded in the Patent and Trademark Office at Reel. No. \_\_\_\_\_ Frame No. \_\_\_\_\_ (or a copy of which is attached).

_____	Customer Number or Bar Code Label	_____
	or	(Insert Customer No. or Attach Bar Code Label here)
<b>X</b>	Correspondence Address Below	

Country U.S.A. TELEPHONE (408) 720-8300 FAX (408) 720-9397

Name (PRINT/TYPE): Tarek N. Fahmi Registration No.: 41,402  
Signature: [Signature] Date: 4/26/01

**FEE TRANSMITTAL FOR FY 2001****TOTAL AMOUNT OF PAYMENT (\$)** \$710.00**Complete if Known:****Application No.** Not Yet Assigned**Filing Date** Herewith**First Named Inventor** J.J. Garcia-Luna-Aceves**Group Art Unit** Not Yet Assigned**Examiner Name** Not Yet Assigned**Attorney Docket No.** 5543P004**METHOD OF PAYMENT (check one)**

1. ☒ **The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:**

**Deposit Account Number** 02-2666  
**Deposit Account Name** \_\_\_\_\_

☒ **Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17**

☐ **Applicant claims small entity status. See 37 CFR 1.27**

2. \_\_\_\_\_ **Payment Enclosed:** \_\_\_\_\_ **Check**  
 \_\_\_\_\_ **Credit Card**  
 \_\_\_\_\_ **Money Order**  
 \_\_\_\_\_ **Other**

**FEE CALCULATION****1. BASIC FILING FEE**

<u>Large Entity</u>		<u>Small Entity</u>		<u>Fee Description</u>	<u>Fee Paid</u>
<u>Fee</u>	<u>Fee</u>	<u>Fee</u>	<u>Fee</u>		
<u>Code</u>	<u>(\$)</u>	<u>Code</u>	<u>(\$)</u>		
101	710	201	355	Utility application filing fee	<u>\$710</u>
106	320	206	160	Design application filing fee	_____
107	490	207	245	Plant filing fee	_____
108	710	208	355	Reissue filing fee	_____
114	150	214	75	Provisional application filing fee	_____

**SUBTOTAL (1)** \$ 710.00**2. EXTRA CLAIM FEES**

		<u>Extra Claims</u>	<u>Fee from below</u>	<u>Fee Paid</u>
<b>Total Claims</b>	<u>15</u>	- 20** = <u>0</u>	X <u>\$18</u>	= <u>\$0</u>
<b>Independent Claims</b>	<u>2</u>	- 3** = <u>0</u>	X <u>\$80</u>	= <u>\$0</u>
<b>Multiple Dependent</b>				= _____

**\*\*Or number previously paid, if greater; For Reissues, see below.**

<u>Large Entity</u>		<u>Small Entity</u>		<u>Fee Description</u>
<u>Fee</u>	<u>Fee</u>	<u>Fee</u>	<u>Fee</u>	
<u>Code</u>	<u>(\$)</u>	<u>Code</u>	<u>(\$)</u>	
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

**SUBTOTAL (2)** \$ 0.00

# FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	_____
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	_____
139	130	139	130	Non-English specification	_____
147	2,520	147	2,520	For filing a request for ex parte reexamination	_____
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	_____
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	_____
115	110	215	55	Extension for reply within first month	_____
116	390	216	195	Extension for reply within second month	_____
117	890	217	445	Extension for reply within third month	_____
118	1,390	218	695	Extension for reply within fourth month	_____
128	1,890	228	945	Extension for reply within fifth month	_____
119	310	219	155	Notice of Appeal	_____
120	310	220	155	Filing a brief in support of an appeal	_____
121	270	221	135	Request for oral hearing	_____
138	1,510	138	1,510	Petition to institute a public use proceeding	_____
140	110	240	55	Petition to revive - unavoidable	_____
141	1,240	241	620	Petition to revive - unintentional	_____
142	1,240	242	620	Utility issue fee (or reissue)	_____
143	440	243	220	Design issue fee	_____
144	600	244	300	Plant issue fee	_____
122	130	122	130	Petitions to the Commissioner	_____
123	50	123	50	Processing fee under 37 CFR 1.17(q)	_____
126	180	126	180	Submission of Information Disclosure Stmt	_____
581	40	581	40	Recording each patent assignment per property (times number of properties)	_____
146	710	246	355	For filing a submission after final rejection (see 37 CFR 1.129(a))	_____
149	710	249	355	For each additional invention to be examined (see 37 CFR 1.129(b))	_____
179	710	279	355	Request for Continued Examination (RCE)	_____
169	900	169	900	Request for expedited examination of a design application	_____
195	300	195	300	Publication fee for early, voluntary, or normal publication	_____
196	300	196	300	Publication fee for republication	_____
194	130	194	130	Request for voluntary publication or republication	_____
098	130	098	130	Processing fee under 37 CFR 1.17(i)	_____
091	1,240	091	1,240	Acceptance of unintentionally delayed claim for priority	_____

Other fee (specify) \_\_\_\_\_

Other fee (specify) \_\_\_\_\_

**SUBTOTAL (3) \$ 0.00**

\*Reduced by Basic Filing Fee Paid

## SUBMITTED BY:

Typed or Printed Name: Tarek N. Fahmi

Signature: [Signature] Date: 4/26/01

Reg. Number: 41,402 Telephone Number: 408.947.8200

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.